COMMUNIQUÉS West-GlobeNewswire

ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
28/09/2017
Press release Leuven, Belgium, 28 th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today [...]
UPDATE ON VOLUNTARY OFFER FOR WEIFA ASA - ACCEPTANCES AT APPROXIMATELY 90.3 %
28/09/2017
Reference is made to the offer document dated 11 September 2017 regarding Karo Pharma AB's ("Karo Pharma") conditional voluntary offer (the "Voluntary Offer") to acquire all of the shares in Weifa ASA ("Weifa") at NOK [...]
Terveystalo Plc applies for its shares to be listed on the Official List of Nasdaq Helsinki Ltd
28/09/2017
TERVEYSTALO PLC STOCK EXCHANGE RELEASE September 28, 2017 at 15:55 pm EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL [...]
Auris Medical Announces Transfer to Nasdaq Capital Market
28/09/2017
Zug, Switzerland, September 28, 2017 - Auris Medical Holding AG (the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, [...]
ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
28/09/2017
Presentation highlights the use of ProMIS' proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Sept. 28, 2017 ( [...]
Allergy Therapeutics: Preliminary Results
28/09/2017
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Preliminary Results 28 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy [...]
European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product
28/09/2017
The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed by IBT for the development of IBP-9414 for the prevention of [...]
Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study
28/09/2017
Press Release 28 September 2017 Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study --Topline Safety and Immune Response Data Support Continued Development of Ilixadencel in Liver Cancer-- [...]
Wraptor présente sa nouvelle release Jeebop MSSanté
28/09/2017
Wraptor, éditeur de solutions dédiées au monde de la santé, premier éditeur à connecter un site pilote lors de l'expérimentation de l'ASIP en 2014, annonce la disponibilité de la nouvelle version de Jeebop MSSanté [...]
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
28/09/2017
Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with Shenzhen China Resources [...]
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
28/09/2017
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and Chemistry Technologies [...]
Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
28/09/2017
Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union - First targeted biologic in the European Union to receive [...]
Sanofi et Regeneron annoncent l'approbation de Dupixent® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte
28/09/2017
Sanofi et Regeneron annoncent l'approbation de Dupixent ® (dupilumab) dans l'Union européenne pour le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier médicament biologique ciblé à bénéficier d [...]
TiGenix to participate and present at key investor and business development meetings
28/09/2017
PRESS RELEASE TiGenix to participate and present at key investor and business development meetings Leuven (BELGIUM) - September 28, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]
TiGenix participera à d'importantes réunions d'investisseurs et de développement d'affaires
28/09/2017
COMMUNIQUÉ DE PRESSE I TiGenix participera à d'importantes réunions d'investisseurs et de développement d'affaires Louvain (BELGIQUE) - 28 septembre 2017, 07h. CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), [...]
NuCana plc Announces Pricing of Initial Public Offering
28/09/2017
EDINBURGH, United Kingdom, Sept. 28, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying [...]
ProQR annonce les premiers résultats positifs d'une étude de Phase 1b de QR-010 chez des sujets atteints de mucoviscidose
28/09/2017
Principaux résultats Le QR-010 s'est révélé sûr et bien toléré pour toutes les doses de cet essai sans événements indésirables graves liés au traitement. Une amélioration cliniquement significative des symptômes [...]
Crown Bioscience nomme Laurie Heilmann à la direction des affaires commerciales ; ce cadre dirigeant apporte à cette fonction toute son expertise en matière de stratégie mondiale et de leadership c...
28/09/2017
SANTA CLARA, Californie, le 28 septembre 2017 (GLOBE NEWSWIRE) - Crown Bioscience , filiale en propriété exclusive de Crown Bioscience International (TWSE : code boursier 6554) et société internationale de services de [...]
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
28/09/2017
Leuven, Belgium, 27 th September, 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that [...]

Pages